A practical NICE-based framework

Atrial fibrillation (AF) may cause palpitations, breathlessness, dizziness or fatigue. However, some people have no symptoms.

Early detection matters because AF increases the risk of thromboembolic stroke. Primary care has a central role in finding AF, confirming the rhythm and ensuring that eligible patients receive anticoagulation.

Watch the A4Medicine video:
AF Detection and Stroke Prevention: A Practical Primary Care Framework based on NICE guidance.

The video is best supported by a focused NICE-based companion article rather than duplicating the existing general AF pages. The current NICE guideline remains NG196, published on 27 April 2021 and last updated on 30 June 2021. (Nice)

Publishing details

Page title: Atrial Fibrillation Detection and Stroke Prevention in Primary Care
SEO title: AF Detection and Stroke Prevention | Primary Care
Suggested slug: atrial-fibrillation-detection-stroke-prevention-primary-care
Meta description: A practical NICE-based guide to detecting AF, confirming the diagnosis, assessing stroke and bleeding risk, and starting anticoagulation safely.
Category: Cardiovascular medicine
Tags: Atrial fibrillation, AF, stroke prevention, anticoagulation, DOAC, CHA₂DS₂-VASc, ORBIT, primary care
Review date: July 2026

Atrial Fibrillation Detection and Stroke Prevention in Primary Care

A practical NICE-based framework

Atrial fibrillation (AF) may cause palpitations, breathlessness, dizziness or fatigue. However, some people have no symptoms.

Early detection matters because AF increases the risk of thromboembolic stroke. Primary care has a central role in finding AF, confirming the rhythm and ensuring that eligible patients receive anticoagulation.

Watch the A4Medicine video:
AF Detection and Stroke Prevention: A Practical Primary Care Framework based on NICE guidance.

AF in Primary Care: Four Key Actions

1. Detect Possible Atrial Fibrillation

Perform manual pulse palpation when a patient presents with:

• Breathlessness

• Palpitations

• Syncope or dizziness

• Chest discomfort

• Stroke or transient ischaemic attack (TIA)

• An unexplained irregular pulse

AF commonly produces an irregularly irregular pulse, but pulse examination alone cannot confirm the diagnosis.[1]

Wearable or Smartwatch Alert

A wearable-device alert may identify an irregular rhythm.

However:

• Treat the alert as a prompt for assessment.

• Review symptoms and pulse.

• Arrange an appropriate electrocardiogram (ECG).

• Do not start long-term anticoagulation solely from an unverified consumer-device alert.

2. Confirm AF with an ECG

Arrange a 12-lead ECG when an irregular pulse is detected, whether or not the patient has symptoms.[1]

Typical ECG features include:

• Irregularly irregular ventricular rhythm

• No consistent P waves

• Variable R–R intervals

Suspected Paroxysmal AF

A normal resting ECG does not exclude intermittent AF.

Choose a monitoring period long enough to capture a typical episode.[1,2]

🚩 Red Flags: Arrange Emergency Assessment

Escalate urgently if suspected or confirmed AF is accompanied by:

• Haemodynamic instability

• Hypotension, shock or altered consciousness

• Ongoing cardiac chest pain

• Severe breathlessness or pulmonary oedema

• Acute heart failure

• Syncope with ongoing cardiovascular compromise

• New focal neurological symptoms suggesting stroke

• A very rapid ventricular rate with severe symptoms

Do not delay emergency treatment to complete routine primary-care risk scoring.

3. Assess Stroke Risk: CHA₂DS₂-VASc

Use the CHA₂DS₂-VASc score in people with:

• Symptomatic or asymptomatic AF

• Paroxysmal, persistent or permanent AF

• Atrial flutter

• Continuing risk of recurrence after cardioversion or ablation

CHA₂DS₂-VASc Score

Use only one age category.

NICE Anticoagulation Thresholds

A direct-acting oral anticoagulant (DOAC) is usually preferred when anticoagulation is indicated and a DOAC is suitable.[1,3]

Important Points

• Symptoms do not determine stroke risk.

• Paroxysmal AF still carries a stroke risk.

• Do not use aspirin alone for AF-related stroke prevention.

• Do not withhold anticoagulation solely because of age or falls risk.

• Do not stop anticoagulation only because AF is no longer detectable.

• After cardioversion or ablation, base long-term anticoagulation on stroke risk, bleeding risk and patient preference.[1]

4. Assess Bleeding Risk: ORBIT

Use the ORBIT bleeding-risk score when considering or reviewing anticoagulation.

ORBIT Interpretation

A high ORBIT score is not an automatic reason to withhold anticoagulation. Use it to support shared decision-making, correct modifiable risks and plan closer monitoring.[1,4]

Address Modifiable Bleeding Risks

Review:

• Uncontrolled hypertension

• Anaemia or suspected gastrointestinal blood loss

• Renal impairment

• Excess alcohol

• Concurrent aspirin or other antiplatelet treatment

• Non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen

• Other interacting medicines

• Poor adherence

• Poor international normalised ratio (INR) control in patients taking warfarin

Anticoagulation Decision Flow

Suspected AF
     ↓
Manual pulse assessment
     ↓
Irregular pulse or strong clinical suspicion
     ↓
12-lead ECG
     ↓
AF not captured but still suspected?
     ├── Yes → Ambulatory or event monitoring
     └── No
          ↓
Confirmed AF or atrial flutter
          ↓
Check for emergency features
          ├── Present → Emergency assessment
          └── Absent
               ↓
Calculate CHA₂DS₂-VASc + ORBIT
               ↓
Discuss benefits, bleeding risk and preferences
               ↓
Anticoagulation indicated?
     ├── Yes → Check suitability, renal function, dose and interactions
     └── No  → Document decision and reassess when risk changes
               ↓
Review after initiation and at least annually

Starting a DOAC: Primary-Care Safety Checklist

Before prescribing:

• Confirm the indication and documented ECG diagnosis.

• Record body weight.

• Check blood pressure.

• Request full blood count (FBC).

• Check liver function tests (LFTs).

• Check urea and electrolytes.

• Calculate creatinine clearance (CrCl) using Cockcroft–Gault.

• Check baseline clotting screen.

• Review prescribed, over-the-counter and herbal medicines.

• Check for antiplatelets, NSAIDs and significant drug interactions.

• Choose the licensed dose for the indication, CrCl, age, weight and interacting medicines.

• Confirm that a DOAC is suitable.

Do not use estimated glomerular filtration rate alone for DOAC dosing. It may overestimate renal function in some patients.[5,6]

When a DOAC May Be Unsuitable

Seek specialist or anticoagulation advice when there is:

• A mechanical prosthetic heart valve

• Moderate-to-severe mitral stenosis

• Severe renal impairment

• Significant active liver disease

• Active major bleeding

• Pregnancy or breastfeeding

• A major interacting medicine

• Uncertainty about the correct agent or dose

Warfarin or another specialist-led strategy may be required.

Patient Counselling

Explain:

• Anticoagulation reduces stroke risk; it does not correct the heart rhythm.

• Doses should be taken exactly as prescribed.

• Missed-dose advice differs between DOACs.

• The patient should not double a dose unless specifically instructed.

• Seek help for persistent or significant bleeding.

• Report black stools, blood in urine, vomiting blood or unexplained severe bruising.

• Seek emergency help after a significant head injury.

• Check before starting aspirin, ibuprofen or other new medicines.

• Inform dentists and other clinicians about anticoagulant treatment.

• Carry an anticoagulant alert card.

Monitoring After Starting a DOAC

Initial Review

Review approximately one month after starting or changing treatment.

Check:

• Adherence

• Bleeding or bruising

• Symptoms of anaemia

• Stroke or TIA symptoms

• Adverse effects

• New medicines and interactions

• Whether the dose remains correct

Ongoing Review

Once stable, review at least annually. Include:

• FBC

• LFTs

• Urea and electrolytes

• Serum creatinine and calculated CrCl

• Weight where relevant to dosing

• Adherence

• Bleeding events

• Thromboembolic events

• New medicines

• CHA₂DS₂-VASc and ORBIT reassessment

Monitor more frequently in people who:

• Are older than 75 years or frail

• Have CrCl below 60 mL/min

• Have changing renal or hepatic function

• Develop an acute illness, dehydration or infection

• Start medicines that affect renal function, hepatic function or bleeding risk[5]

Primary-Care Audit Searches

Consider searches for patients who have:

• AF but no recorded CHA₂DS₂-VASc score

• AF but no recent ORBIT score

• CHA₂DS₂-VASc ≥2 but no anticoagulant

• Aspirin monotherapy for AF-related stroke prevention

• A DOAC without recent FBC, LFTs or renal-function testing

• A potentially incorrect DOAC dose

• AF coded as “resolved” but anticoagulation stopped without documented risk assessment

• A low stroke-risk score that has not been reviewed after ageing or a new diagnosis

Key Messages

Detect: Check the pulse and investigate suspicious symptoms.

Confirm: Diagnose AF with ECG evidence. Use ambulatory monitoring for intermittent symptoms.

Protect: Calculate CHA₂DS₂-VASc and ORBIT. Offer anticoagulation when indicated.

Perfect: Review adherence, dosing, renal function, interactions and bleeding risk regularly.

References

1. National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management. NICE guideline NG196. Published April 2021; updated June 2021. (Nice)

2. National Institute for Health and Care Excellence. Algorithms for atrial fibrillation diagnosis and management. (Nice)

3. Jones NR, Taylor CJ, Hobbs FDR, Bowman L, Casadei B. Atrial fibrillation: NICE 2021 update and the focus on anticoagulation. British Journal of General Practice. 2022;72(717):193–195. (PubMed Central (PMC))

4. O’Brien EC, Simon DN, Thomas LE, et al. The ORBIT bleeding score: a simple bedside score to assess bleeding risk in atrial fibrillation. European Heart Journal. 2015;36(46):3258–3264. (PubMed Central (PMC))

5. Specialist Pharmacy Service. DOACs: direct oral anticoagulants monitoring. (SPS - Specialist Pharmacy Service)

6. Medicines and Healthcare products Regulatory Agency. Direct-acting oral anticoagulants: reminder of bleeding risk, availability of reversal agents and importance of renal-function-based dosing. (GOV.UK)

This article is intended for clinical education. Follow the current BNF, relevant summary of product characteristics, local formulary and local anticoagulation pathways when prescribing.